DUBLIN--(BUSINESS WIRE)--The "Global Syndromic Multiplex Diagnostic Markets 2019 to 2023 - Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI etc.), by Country, with Market Analysis, Executive Guides and Customization." report has been added to ResearchAndMarkets.com's offering.
Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance.
The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.
The report forecasts the market size out to 2023. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.
Market Dynamics
Factors Driving Growth
- Speed of Diagnosis
- Effect of Syndromic Testing on Costs
- Point of Care Advantage
- Syndrome Testing, Accuracy and Diagnostic Risk
- Single Visits
- Improvement in Outcomes
Factors Limiting Growth
- Lower Prices
- Infectious Disease is Declining
- Wellness Hurts
- Economic Growth Improves Living Standards
Key Topics Covered
1. Introduction and Market Definition
2. The Infectious Diseases - Guide to the Pathogens
3. Industry Overview
4. Market Trends
5. Syndromic Testing Recent Developments
- QIAGEN enters into agreement to acquire STAT-Dx
- GA-EMS receives diagnostic device contract
- Biocartis & Immunexpress Sign Partnership for Sepsis
- Alveo Closes Financing to Create Accessible Diagnostics Devices
- Siemens Healthineers completes takeover of Fast Track Diagnostics
- Chembio and FIND to Develop Point-of-Care Multiplex Test
- Applied BioCode Receives CE Mark for 18-plex Gastrointestinal Pathogen Panel
- Rapid Molecular Flu Tests Gain Ground
- Cepheid Receives FDA Clearance and CLIA Waiver for Xpert Xpress Flu Test
- bioMerieux seeks FDA Clearance of Pneumonia Panel
- Mobidiag Announces Release of a Multiplex qPCR Test for Detection of Antibiotic Resistant Bacteria
- Fast Track Diagnostics Gets CE Mark for Real-Time PCR Detection of High-Risk HPV
- SEEGENE develops Multiplex PCR tests in 4 days
-
and more...
6. Profiles of Key Syndromic Testing Companies
7. Global Market Size
8. Global Market by Syndrome
9. Panel Testing Market - Volumes and Price Forecast with MDx Share
Companies Profiled
- Abbott Diagnostics (Alere)
- Accelerate Diagnostics
- Akonni Biosystems
- Alveo Technologies
- Atlas Genetics
- Aus Diagnostics
- BARDA
- BD Diagnostics
- Bio-Rad Laboratories
- BioFire Diagnostics
- Biocartis
- bioMerieux
- Chembio
- Cue Health
- Curetis
- Diagenode Diagnostics
- GA-EMS
- GenMark Dx
- Great Basin Scientific
- Hologic
- Immunexpress
- Janssen Diagnostics
- Lexigene
- Mobidiag
- Nanomix
- Primerdesign
- Qiagen (Statdx)
- Quantumdx
- Righton
- SkylineDx
- T2 Biosystems
- Thermo Fisher Scientific
- Vela
- Veramarx
-
and more...
For more information about this report visit https://www.researchandmarkets.com/research/jvpxzp/global_syndromic?w=4
